prikaz prve stranice dokumenta Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype
  Download
PDF 922 KB
Scientific paper - Original scientific paper
Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype
Haematologica, 104 (2019), 6; 1168-1175. https://doi.org/10.3324/haematol.2018.204826
Baron, Frédéric; Stevens-Kroef, Marian; Kicinski, Michal; Meloni, Giovanna; Muus, Petra; Marie, Jean-Pierre; Halkes, Constantijn J.M.; Thomas, Xavier; Vrhovac, Radovan; Albano, Francesco; Lefrère, François; Sica, Simona; Mancini, Marco; Venditti, Adriano; Hagemeijer, Anne; Jansen, Joop H.; Amadori, Sergio; de Witte, Theo; Willemze, Roelof; Suciu, Stefan More authors...

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Baron, F., Stevens Kroef, M., Kicinski, M., Meloni, G., Muus, P., Marie, J. P. ... Suciu, S. (2019). Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype. Haematologica, 104. (6), 1168-1175. doi: 10.3324/haematol.2018.204826

Baron, Frédéric, et al. "Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype." Haematologica, vol. 104, no. 6, 2019, pp. 1168-1175. https://doi.org/10.3324/haematol.2018.204826

Baron, Frédéric, Marian Stevens Kroef, Michal Kicinski, Giovanna Meloni, Petra Muus, Jean Pierre Marie, Constantijn J.M. Halkes, et al. "Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype." Haematologica 104, no. 6 (2019): 1168-1175. https://doi.org/10.3324/haematol.2018.204826

Baron, F., et al. (2019) 'Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype', Haematologica, 104(6), pp. 1168-1175. doi: 10.3324/haematol.2018.204826

Baron F, Stevens Kroef M, Kicinski M, Meloni G, Muus P, Marie JP, and sur.. Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype. Haematologica [Internet]. 2019 June [cited 2024 April 29];104(6):1168-1175. doi: 10.3324/haematol.2018.204826

F. Baron, et al., "Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype", Haematologica, vol. 104, no. 6, pp. 1168-1175, June 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:056120. [Accessed: 29 April 2024]

Metadata
Title (english)Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype
AuthorFrédéric Baron
AuthorMarian Stevens-Kroef
AuthorMichal Kicinski
AuthorGiovanna Meloni
AuthorPetra Muus
AuthorJean-Pierre Marie
AuthorConstantijn J.M. Halkes
AuthorXavier Thomas
AuthorRadovan Vrhovac
AuthorFrancesco Albano
AuthorFrançois Lefrère
AuthorSimona Sica
AuthorMarco Mancini
AuthorAdriano Venditti
AuthorAnne Hagemeijer
AuthorJoop H. Jansen
AuthorSergio Amadori
AuthorTheo de Witte
AuthorRoelof Willemze
AuthorStefan Suciu
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Monosomal karyotype confers a poor prognosis in patients with acute myeloid leukemia. Here, we determined the impact of the type of remission-induction chemotherapy and the impact of having a donor in younger acute myeloid leukemia patients with a monosomal karyotype included in two phase III trials. In the first trial patients were randomized to receive either daunorubicin, mitoxantrone, or idarubicin in addition to standard-dose cytarabine and etoposide for induction chemotherapy. In the second trial patients were randomized to standard-dose cytarabine or high-dose cytarabine induction, both with daunorubicin and etoposide. In both trials, patients who achieved a complete remission with or without complete hematologic recovery underwent allogeneic hematopoietic stem cell transplantation if they had a donor; otherwise, they underwent autologous transplantation. In comparison to patients with intermediate-risk cytogenetics without a monosomal karyotype (n=1,584) and with adverse cytogenetics without a monosomal karyotype (n=218), patients with a monosomal karyotype (n=188) were more likely not to achieve a complete remission with or without count recovery [odds ratio=2.85, 95% confidence interval (95%, CI): 2.10-3.88] and had shorter overall survival [hazard ratio, (HR)=2.44, 95% CI: 2.08-2.88]. There was no impact of the type of anthracycline or of the dose of cytarabine on outcomes in patients with a monosomal karyotype. Among monosomal karyo type patients who achieved a complete remission with or without count recovery, HLA-identical related donor availability was associated with longer survival from complete remission with or without count recovery (HR=0.59, 95% CI: 0.37-0.95). ClinicalTrials.gov identifiers: AML-10: NCT00002549; AML-12: NCT00004128.
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleHaematologica
Numberingvol. 104, no. 6, pp. 1168-1175
p-ISSN0390-6078
DOIhttps://doi.org/10.3324/haematol.2018.204826
URN:NBNurn:nbn:hr:105:056120
Publication2019-06
Document URLhttp://doi.org/10.3324/haematol.2018.204826
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 09:59:25